RLY-2608 is an oral allosteric pan-mutant isoform-selective PI3Kα inhibitor that was discovered using MD modeling and cryo-EM to identify allosteric networks and opportunities for small molecules, followed by DEL screening.
MedKoo Cat#: 125816
Name: RLY-2608
CAS#: 2733573-94-7
Chemical Formula: C29H14ClF5N6O2
Exact Mass: 608.0800
Molecular Weight: 608.91
Elemental Analysis: C, 57.20; H, 2.32; Cl, 5.82; F, 15.60; N, 13.80; O, 5.25
The following data is based on the product molecular weight 608.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
4040.jpg "Enbezotinib")
